EMA recommends restricting cilostazol use for PAD
The Europeans Medicines Agency has recommended restricting the use of cilostazol in patients with intermittent claudication. Use should be avoided in those with cardiac problems or on dual anticoagulants.
CONCLUSIONS: Based on our experience, IIA embolization does cause buttock claudication of a certain degree. However, the most of them experienced mild discomfort rather than such symptoms severely affect their quality of life. Considering the risks of general anesthesia and complications of surgical procedures, IIA reconstruction along with EVAR may not be necessary. PMID: 32214071 [PubMed - as supplied by publisher]
PMID: 32212916 [PubMed - as supplied by publisher]
Prospective observational multicenter study (time period not reported).
Abstract A 79-year-old woman presented to the emergency room with a chief complaint of headache of 1 month's duration. Her medical history consisted of hypertension, congestive heart failure, anemia, chronic kidney disease, and hyperlipidemia. She reported the headache as waxing and waning, and occurring bilaterally in the frontal and occipital regions. On examination, she was found to have mild right-sided ptosis and possible early right-sided papilledema. She was also found to have bilateral shoulder tenderness and scalp tenderness. She denied double vision, vision changes, or jaw claudication. PMID: 321674...
Multiple societal guidelines recommend medical optimization and exercise therapy for patients with claudication prior to lower extremity revascularization (LER). However, the application of those guidelines in practice remains unknown. Our hypothesis is that vascular surgeons (VS) are more adherent to guidelines compared to non-vascular surgeons treating claudication.
Condition: Peripheral Arterial Disease Interventions: Drug: Rivaroxaban; Drug: ASA Sponsors: Poznan University of Medical Sciences; Poznan University of Physical Education; Institute of Human Genetics, Polish Academy of Sciences Not yet recruiting
Patients with peripheral artery disease and associated intermittent claudication can experience significant short-term (for instance, day-to-day) variations in their walking ability. This variability is often viewed as a complication in establishing reliable baseline walking performance levels for individual patients in multi-patient supervised walking programs.
Hernandez et al.1 have recently published a study that aimed to characterize physical activity and sedentary behavior in patients with peripheral artery disease (PAD) and intermittent claudication. Although interesting, their article contains incorrect information and questionable data analysis and interpretation.